This just in….
An FDA panel suggests that MRI drugs made by Bayer AG and General Electric Co. should be restricted to patients without severe kidney problems amid reports that they may cause nephrogenic systemic fibrosis (NSF), a potentially fatal skin condition. Omniscan by GE and Bayer’s Magnevist were among seven FDA-approved products containing gadolinium and used in MRIs that the panel looked at, according to the Dow Jones report.
Science Daily reports today on a study in the December 9 issue of the Journal of the American Medical Association that found about 20% of dialysis patients undergoing a percutaneous coronary intervention such as an angioplasty receive medication that may increase their risk for in-hospital bleeding.
We’ll be watching these developments. Count on Sokolove Law to protect your rights.